91 related articles for article (PubMed ID: 10456489)
21. Multiple sclerosis and exposure to organic solvents, investigated by genetic polymorphisms of the GSTM1 and CYP2D6 enzyme systems.
Landtblom AM; Wastenson M; Ahmadi A; Söderkvist P
Neurol Sci; 2003 Nov; 24(4):248-51. PubMed ID: 14658041
[TBL] [Abstract][Full Text] [Related]
22. Metabolic gene polymorphisms and risk of dysmenorrhea.
Wu D; Wang X; Chen D; Niu T; Ni J; Liu X; Xu X
Epidemiology; 2000 Nov; 11(6):648-53. PubMed ID: 11055624
[TBL] [Abstract][Full Text] [Related]
23. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
24. Lack of association between human longevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci.
Muiras ML; Verasdonck P; Cottet F; Schächter F
Hum Genet; 1998 May; 102(5):526-32. PubMed ID: 9654200
[TBL] [Abstract][Full Text] [Related]
25. CYP2D6 genetic polymorphisms are associated with susceptibility to pituitary tumors.
Gomes L; Lemos MC; Paiva I; Ribeiro C; Carvalheiro M; Regateiro FJ
Acta Med Port; 2005; 18(5):339-43. PubMed ID: 16611538
[TBL] [Abstract][Full Text] [Related]
26. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
[TBL] [Abstract][Full Text] [Related]
27. Study of genetic polymorphism of xenobiotic enzymes in acute leukemia.
Eyada TK; El Ghonemy EG; El Ghoroury EA; El Bassyouni SO; El Masry MK
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):489-95. PubMed ID: 17581325
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphism of CYP2D6∗2 C→T 2850, GSTM1, NQO1 genes and their correlation with biomarkers in manganese miners of Central India.
Vinayagamoorthy N; Krishnamurthi K; Devi SS; Naoghare PK; Biswas R; Biswas AR; Pramanik S; Shende AR; Chakrabarti T
Chemosphere; 2010 Nov; 81(10):1286-91. PubMed ID: 20851451
[TBL] [Abstract][Full Text] [Related]
29. Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias.
Aydin-Sayitoglu M; Hatirnaz O; Erensoy N; Ozbek U
Am J Hematol; 2006 Mar; 81(3):162-70. PubMed ID: 16493615
[TBL] [Abstract][Full Text] [Related]
30. Polymorphisms at CYP and GST gene loci. Prevalence in the Indian population.
Buch S; Kotekar A; Kawle D; Bhisey R
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):553-5. PubMed ID: 11699625
[TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphisms of CYP2D6, GSTM1, and GSTT1 genes and bladder cancer risk in North India.
Sobti RC; Al-Badran AI; Sharma S; Sharma SK; Krishan A; Mohan H
Cancer Genet Cytogenet; 2005 Jan; 156(1):68-73. PubMed ID: 15588859
[TBL] [Abstract][Full Text] [Related]
32. Host determinants of DNA alkylation and DNA repair activity in human colorectal tissue: O(6)-methylguanine levels are associated with GSTT1 genotype and O(6)-alkylguanine-DNA alkyltransferase activity with CYP2D6 genotype.
Povey AC; Hall CN; Badawi AF; Cooper DP; Guppy MJ; Jackson PE; O'Connor PJ; Margison GP
Mutat Res; 2001 Aug; 495(1-2):103-15. PubMed ID: 11448648
[TBL] [Abstract][Full Text] [Related]
33. Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6.
Worrall SF; Corrigan M; High A; Starr D; Matthias C; Wolf CR; Jones PW; Hand P; Gilford J; Farrell WE; Hoban P; Fryer AA; Strange RC
Pharmacogenetics; 1998 Oct; 8(5):433-9. PubMed ID: 9825835
[TBL] [Abstract][Full Text] [Related]
34. Correlation between cytochrome P-450 CYP2D6 (CYP2D6) genotype and phenotype.
Chen SQ; Wedlund PJ
Zhongguo Yao Li Xue Bao; 1999 Jul; 20(7):585-8. PubMed ID: 10678117
[TBL] [Abstract][Full Text] [Related]
35. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.
Dandara C; Masimirembwa CM; Magimba A; Sayi J; Kaaya S; Sommers DK; Snyman JR; Hasler JA
Eur J Clin Pharmacol; 2001 Apr; 57(1):11-7. PubMed ID: 11372584
[TBL] [Abstract][Full Text] [Related]
36. CYP2D6 polymorphism in systemic lupus erythematosus patients.
Kortunay S; Bozkurt A; Bathum L; Basci NE; Calgüneri M; Brøsen K; Kayaalp SO
Eur J Clin Pharmacol; 1999 Mar; 55(1):21-5. PubMed ID: 10206080
[TBL] [Abstract][Full Text] [Related]
37. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.
López M; Guerrero J; Jung-Cook H; Alonso ME
Eur J Clin Pharmacol; 2005 Nov; 61(10):749-54. PubMed ID: 16249913
[TBL] [Abstract][Full Text] [Related]
38. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis.
Crescenti A; Mas S; Gassó P; Baiget M; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):992-7. PubMed ID: 17714084
[TBL] [Abstract][Full Text] [Related]
40. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
